Do Harm Submits Comment to FDA Urging Oversight of Off-Label Estrogen Use in Males
In December 2025, Do No Harm co-signed a citizen petition asking the Food and Drug Administration (FDA) to address the risks of the widespread off-label prescription of estrogen to males for the purpose of so-called “gender-affirming care.”
